Drug Revolving Fund Strengthened Hypertension Medicine Access in 60 Nigerian Primary Care Centers
A drug revolving fund built into hypertension care in Nigeria’s Federal Capital Territory reached every participating primary healthcare centre and improved the systems needed to keep blood pressure medicines moving through primary care. In a setting where treatment fails as much from stock gaps and weak accounting as from clinical inertia, the program treated medication access as an operational problem with direct cardiovascular consequences.
From June 2022 through December 2023, the Hypertension Treatment in Nigeria Programme embedded the fund across 60 primary healthcare centres. The work focused on a basic but frequently underengineered requirement: if clinicians prescribe antihypertensive therapy, the pharmacy shelf has to hold the drug, the patient has to be able to pay an affordable price, and the facility has to know where the money and stock went afterward. Without that chain, treatment initiation and continuation break down quickly.
A Health-System Intervention Built Around Existing Primary Care Supply Lines
The program design was deliberately practical. Instead of creating a parallel distribution channel, the team leveraged existing supply systems, wrote medication and financial management protocols, trained site staff, and carried out supportive supervision visits that included joint problem solving. Those choices matter because a revolving fund can fail if it is treated as a simple procurement exercise rather than an ongoing financial and logistical cycle.
The framework used to describe the work separated the implementation process into exploration, preparation, implementation, and sustainment. A second implementation framework captured reach, effectiveness, adoption, implementation, and maintenance. In policy terms, this is a useful distinction: the intervention did not stop at getting medicines into the facility once. It examined whether the system could keep functioning over time.
Every one of the 60 primary healthcare centres participated, giving the program 100% reach. In a primary care network, that kind of penetration is operationally meaningful because a partial rollout leaves the highest-risk patients behind, often in the same facilities where hypertension is most likely to be identified late or left untreated.
Adoption Rose as Facilities Moved from Partial to Full Participation
Adoption improved during the implementation period. The proportion of facilities selling DRF-supported medications increased from 80% to 100%, with a p value of 0.01. At the bedside, that shift translates into fewer empty-handed prescriptions and more consistent access to first-line antihypertensive treatment. A revolving fund can only work if patients can actually obtain the medication after the prescription is written; otherwise, the clinical encounter ends before therapy begins.
The improvement in adoption also points to a behavioral and administrative shift inside the facilities. Staff members had to accept the fund as part of routine pharmacy work, not as an added burden layered on top of already strained operations. Supportive supervision and joint problem solving likely helped convert the abstract idea of pooled medicine financing into daily workflow.
One sentence captures the practical consequence plainly: medicines that sit in a supply chain do not lower blood pressure.
Financial Documentation Improved Alongside Medication Availability
Fidelity rose as well, including correct financial documentation from 70% to 100%, with a p value of 0.01. In a revolving fund, documentation is not paperwork for its own sake. It is the mechanism that keeps cash flowing back into replenishment, prevents untracked losses, and allows the program to know whether the stock cycle remains solvent.
That improvement matters for hypertension care because treatment continuity depends on predictable refill availability. Patients with elevated blood pressure are often asymptomatic, so adherence is vulnerable to every obstacle in the path between prescription and refill. When accounting is inaccurate, future restocking is delayed; when restocking is delayed, patients miss doses; when doses are missed, blood pressure control becomes less reliable and the risk of stroke, heart failure, and kidney disease remains elevated.
The report also describes implementation gains in the broader support structure around the fund, including training and supervision. Those components are not ornamental. In low-resource primary care, staff turnover, competing priorities, and uneven pharmacy experience can quickly erode a new financing model unless the program provides repeated operational reinforcement.
Interrupted Time-Series Analysis Sought to Track Dispensing Trends
An interrupted time-series design was used to examine temporal trends in the 3-month rolling average rate of blood pressure-lowering prescriptions dispensed. That analytic choice fits the intervention. A revolving fund is expected to influence dispensing gradually, through stock continuity and improved facility behavior, rather than through an immediate biological effect.
The design also reflects the right clinical question for a health-system intervention: did the facilities actually dispense more antihypertensive medication over time as the fund matured? Even when the pharmacology of blood pressure treatment is well established, access remains the gatekeeper. The intervention targeted that gatekeeper directly.
Why the Model Matters for Hypertension Control in Primary Care
Hypertension programs in primary care often fail at the supply interface before they fail at diagnosis or prescribing. A patient can be screened, labeled hypertensive, and given a treatment plan, yet never stay on therapy if the drug is unavailable or unaffordable. A revolving fund is a financing and stewardship model designed to close that gap by recycling revenue from medicine sales back into replenishment.
In that sense, the intervention works on the infrastructure beneath blood pressure control. Stable procurement supports consistent prescribing; consistent prescribing supports adherence; adherence supports sustained reduction in vascular risk. The clinical logic is straightforward, but the operational work behind it is demanding. Training, stock monitoring, financial reconciliation, and supervision have to function together, or the system drifts back toward intermittent access.
The study’s strongest contribution is its documentation of what it takes to install and maintain such a fund in real-world primary care. The reach was complete, adoption improved, and documentation strengthened over the implementation period. Those are the kinds of implementation outcomes that determine whether hypertension treatment remains available after the initial enthusiasm fades.
The remaining challenge is durability under routine service pressures, especially in facilities that must keep medicines affordable while preserving enough margin to replenish stock. The program shows that a revolving fund can be built into primary care and run across a wide network, but long-term performance will depend on whether the financial and supervisory machinery continues to hold once external support recedes.